{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,4,10]],"date-time":"2026-04-10T22:49:26Z","timestamp":1775861366977,"version":"3.50.1"},"reference-count":31,"publisher":"Elsevier BV","issue":"1","license":[{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2020,1,1]],"date-time":"2020-01-01T00:00:00Z","timestamp":1577836800000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"funder":[{"DOI":"10.13039\/100007582","name":"Alberta Health Services","doi-asserted-by":"publisher","id":[{"id":"10.13039\/100007582","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["clinicalkey.com","clinicalkey.com.au","clinicalkey.es","clinicalkey.fr","clinicalkey.jp","gynecologiconcology-online.net","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Gynecologic Oncology"],"published-print":{"date-parts":[[2020,1]]},"DOI":"10.1016\/j.ygyno.2019.10.021","type":"journal-article","created":{"date-parts":[[2019,11,8]],"date-time":"2019-11-08T10:21:09Z","timestamp":1573208469000},"page":"6-12","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":5,"title":["Genomic heterogeneity in peritoneal implants: A differential analysis of gene expression using nanostring Human Cancer Reference panel identifies a malignant signature"],"prefix":"10.1016","volume":"156","author":[{"given":"Paulette","family":"Mhawech-Fauceglia","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Iyare","family":"Izevbaye","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Tassja","family":"Spindler","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Guisong","family":"Wang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Helena","family":"Hwang","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Damanzoopinder","family":"Samrao","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Ester","family":"Elishaev","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"G. Larry","family":"Maxwell","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kate","family":"Lawrenson","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Kathleen M.","family":"Darcy","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"78","reference":[{"issue":"5","key":"10.1016\/j.ygyno.2019.10.021_bib1","doi-asserted-by":"crossref","first-page":"539","DOI":"10.1053\/hp.2000.8048","article-title":"Ovarian serous borderline tumors: a critical review of the literature with emphasis on prognostic indicators","volume":"31","author":"Seidman","year":"2000","journal-title":"Hum. Pathol."},{"issue":"9","key":"10.1016\/j.ygyno.2019.10.021_bib2","doi-asserted-by":"crossref","first-page":"1165","DOI":"10.1097\/PAS.0000000000000693","article-title":"Low-grade serous carcinoma of the ovary: clinicopathologic analysis of 52 invasive cases and identification of a possible noninvasive intermediate lesion","volume":"40","author":"Ahn","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"issue":"6","key":"10.1016\/j.ygyno.2019.10.021_bib3","doi-asserted-by":"crossref","first-page":"707","DOI":"10.1097\/01.pas.0000164030.82810.db","article-title":"Ovarian serous tumors of low malignant potential (borderline tumors): outcome-based study of 276 patients with long-term (> or\u00a0=5-year) follow-up","volume":"29","author":"Longacre","year":"2005","journal-title":"Am. J. Surg. Pathol."},{"issue":"9","key":"10.1016\/j.ygyno.2019.10.021_bib4","doi-asserted-by":"crossref","first-page":"1155","DOI":"10.1097\/PAS.0000000000000692","article-title":"Classification of extraovarian implants in patients with ovarian serous borderline tumors (tumors of low malignant potential) based on clinical outcome","volume":"40","author":"McKenney","year":"2016","journal-title":"Am. J. Surg. Pathol."},{"issue":"9","key":"10.1016\/j.ygyno.2019.10.021_bib5","doi-asserted-by":"crossref","first-page":"1111","DOI":"10.1097\/00000478-200209000-00002","article-title":"Serous borderline tumors of the ovary: a long-term follow-up study of 137 cases, including 18 with a micropapillary pattern and 20 with microinvasion","volume":"26","author":"Prat","year":"2002","journal-title":"Am. J. Surg. Pathol."},{"issue":"4","key":"10.1016\/j.ygyno.2019.10.021_bib6","doi-asserted-by":"crossref","first-page":"419","DOI":"10.1097\/00000478-200104000-00001","article-title":"Refined diagnostic criteria for implants associated with ovarian atypical proliferative serous tumors (borderline) and micropapillary serous carcinomas","volume":"25","author":"Bell","year":"2001","journal-title":"Am. J. Surg. Pathol."},{"key":"10.1016\/j.ygyno.2019.10.021_bib7","first-page":"649","article-title":"Introduction of WHO Classification of Tumours of Female Reproductive Organs","volume":"vol. 43","author":"Lu","year":"2014"},{"issue":"1","key":"10.1016\/j.ygyno.2019.10.021_bib8","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1002\/path.4293","article-title":"Mutational analysis of BRAF and KRAS in ovarian serous borderline (atypical proliferative) tumours and associated peritoneal implants","volume":"232","author":"Ardighieri","year":"2014","journal-title":"J.\u00a0Pathol."},{"issue":"11","key":"10.1016\/j.ygyno.2019.10.021_bib9","first-page":"2328","article-title":"Evidence for the multifocal origin of bilateral and advanced human serous borderline ovarian tumors","volume":"58","author":"Lu","year":"1998","journal-title":"Cancer Res."},{"issue":"4","key":"10.1016\/j.ygyno.2019.10.021_bib10","doi-asserted-by":"crossref","first-page":"1223","DOI":"10.1016\/S0002-9440(10)62549-7","article-title":"Diverse tumorigenic pathways in ovarian serous carcinoma","volume":"160","author":"Singer","year":"2002","journal-title":"Am. J. Pathol."},{"issue":"6","key":"10.1016\/j.ygyno.2019.10.021_bib11","doi-asserted-by":"crossref","first-page":"484","DOI":"10.1093\/jnci\/95.6.484","article-title":"Mutations in BRAF and KRAS characterize the development of low-grade ovarian serous carcinoma","volume":"95","author":"Singer","year":"2003","journal-title":"J.\u00a0Natl. Cancer Inst."},{"issue":"1","key":"10.1016\/j.ygyno.2019.10.021_bib12","doi-asserted-by":"crossref","first-page":"37","DOI":"10.1097\/00004347-200301000-00009","article-title":"Mutational analysis of K-ras segregates ovarian serous carcinomas into two types: invasive MPSC (low-grade tumor) and conventional serous carcinoma (high-grade tumor)","volume":"22","author":"Singer","year":"2003","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"2","key":"10.1016\/j.ygyno.2019.10.021_bib13","doi-asserted-by":"crossref","first-page":"53","DOI":"10.1002\/mc.10098","article-title":"Molecular determinants of tumor differentiation in papillary serous ovarian carcinoma","volume":"36","author":"Jazaeri","year":"2003","journal-title":"Mol. Carcinog."},{"issue":"4","key":"10.1016\/j.ygyno.2019.10.021_bib14","doi-asserted-by":"crossref","first-page":"496","DOI":"10.1097\/00000478-200404000-00009","article-title":"Grading ovarian serous carcinoma using a two-tier system","volume":"28","author":"Malpica","year":"2004","journal-title":"Am. J. Surg. Pathol."},{"issue":"7","key":"10.1016\/j.ygyno.2019.10.021_bib15","first-page":"663","article-title":"Ovarian serous neoplasms of low malignant potential associated with focal areas of serous carcinoma","volume":"10","author":"Silva","year":"1997","journal-title":"Mod. Pathol."},{"issue":"3","key":"10.1016\/j.ygyno.2019.10.021_bib16","doi-asserted-by":"crossref","first-page":"265","DOI":"10.1097\/01.pgp.0000130049.19643.f6","article-title":"Early recurrence of ovarian serous borderline tumor as high-grade carcinoma: a report of two cases","volume":"23","author":"Parker","year":"2004","journal-title":"Int. J. Gynecol. Pathol."},{"issue":"7","key":"10.1016\/j.ygyno.2019.10.021_bib17","doi-asserted-by":"crossref","first-page":"1007","DOI":"10.1097\/PAS.0b013e31802cbbe9","article-title":"The development of high-grade serous carcinoma from atypical proliferative (borderline) serous tumors and low-grade micropapillary serous carcinoma: a morphologic and molecular genetic analysis","volume":"31","author":"Dehari","year":"2007","journal-title":"Am. J. Surg. Pathol."},{"issue":"4","key":"10.1016\/j.ygyno.2019.10.021_bib18","doi-asserted-by":"crossref","first-page":"431","DOI":"10.1038\/bjc.2016.203","article-title":"ABCB1 (MDR1) induction defines a common resistance mechanism in paclitaxel- and olaparib-resistant ovarian cancer cells","volume":"115","author":"Vaidyanathan","year":"2016","journal-title":"Br. J. Canc."},{"issue":"11","key":"10.1016\/j.ygyno.2019.10.021_bib19","doi-asserted-by":"crossref","first-page":"e0166058","DOI":"10.1371\/journal.pone.0166058","article-title":"Prognostic value and implication for chemotherapy treatment of ABCB1 in epithelial ovarian cancer: a meta-analysis","volume":"11","author":"Sun","year":"2016","journal-title":"PLoS One"},{"issue":"15","key":"10.1016\/j.ygyno.2019.10.021_bib20","doi-asserted-by":"crossref","first-page":"6660","DOI":"10.1158\/0008-5472.CAN-04-3478","article-title":"The CD44 receptor interacts with P-glycoprotein to promote cell migration and invasion in cancer","volume":"65","author":"Miletti-Gonzalez","year":"2005","journal-title":"Cancer Res."},{"issue":"7155","key":"10.1016\/j.ygyno.2019.10.021_bib21","doi-asserted-by":"crossref","first-page":"811","DOI":"10.1038\/nature06046","article-title":"Cdk1 is sufficient to drive the mammalian cell cycle","volume":"448","author":"Santamaria","year":"2007","journal-title":"Nature"},{"issue":"6","key":"10.1016\/j.ygyno.2019.10.021_bib22","doi-asserted-by":"crossref","first-page":"400","DOI":"10.1038\/nrc2657","article-title":"p21 in cancer: intricate networks and multiple activities","volume":"9","author":"Abbas","year":"2009","journal-title":"Nat. Rev. Cancer"},{"issue":"1","key":"10.1016\/j.ygyno.2019.10.021_bib23","doi-asserted-by":"crossref","first-page":"2372","DOI":"10.1038\/s41467-018-04590-1","article-title":"Assembly and activation of the Hippo signalome by FAT1 tumor suppressor","volume":"9","author":"Martin","year":"2018","journal-title":"Nat. Commun."},{"issue":"10","key":"10.1016\/j.ygyno.2019.10.021_bib24","doi-asserted-by":"crossref","first-page":"5165","DOI":"10.1158\/0008-5472.CAN-05-3012","article-title":"Membrane-type 4 matrix metalloproteinase promotes breast cancer growth and metastases","volume":"66","author":"Chabottaux","year":"2006","journal-title":"Cancer Res."},{"issue":"1","key":"10.1016\/j.ygyno.2019.10.021_bib25","doi-asserted-by":"crossref","first-page":"16","DOI":"10.1111\/j.1742-4658.2010.07919.x","article-title":"Roles of matrix metalloproteinases in cancer progression and their pharmacological targeting","volume":"278","author":"Gialeli","year":"2011","journal-title":"FEBS J."},{"issue":"5","key":"10.1016\/j.ygyno.2019.10.021_bib26","doi-asserted-by":"crossref","first-page":"1669","DOI":"10.1073\/pnas.94.5.1669","article-title":"Unexpected genetic and structural relationships of a long-forgotten flavoenzyme to NAD(P)H:quinone reductase (DT-diaphorase)","volume":"94","author":"Zhao","year":"1997","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"20","key":"10.1016\/j.ygyno.2019.10.021_bib27","doi-asserted-by":"crossref","first-page":"13125","DOI":"10.1073\/pnas.202480499","article-title":"Mdm-2 and ubiquitin-independent p53 proteasomal degradation regulated by NQO1","volume":"99","author":"Asher","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"issue":"5","key":"10.1016\/j.ygyno.2019.10.021_bib28","doi-asserted-by":"crossref","first-page":"3099","DOI":"10.1073\/pnas.052706799","article-title":"NQO1 stabilizes p53 through a distinct pathway","volume":"99","author":"Asher","year":"2002","journal-title":"Proc. Natl. Acad. Sci. U. S. A."},{"key":"10.1016\/j.ygyno.2019.10.021_bib29","doi-asserted-by":"crossref","first-page":"115","DOI":"10.1016\/S0076-6879(04)82008-1","article-title":"NAD(P)H:quinone oxidoreductase 1 (NQO1, DT-diaphorase), functions and pharmacogenetics","volume":"382","author":"Ross","year":"2004","journal-title":"Methods Enzymol."},{"key":"10.1016\/j.ygyno.2019.10.021_bib30","doi-asserted-by":"crossref","first-page":"244","DOI":"10.1186\/s12885-015-1271-4","article-title":"High expression of NQO1 is associated with poor prognosis in serous ovarian carcinoma","volume":"15","author":"Cui","year":"2015","journal-title":"BMC Canc."},{"issue":"1","key":"10.1016\/j.ygyno.2019.10.021_bib31","doi-asserted-by":"crossref","first-page":"17","DOI":"10.1186\/s13048-019-0492-6","article-title":"TOP2A as marker of response to pegylated lyposomal doxorubicin (PLD) in epithelial ovarian cancers","volume":"12","author":"Ghisoni","year":"2019","journal-title":"J.\u00a0Ovarian Res."}],"container-title":["Gynecologic Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819316051?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090825819316051?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"}],"deposited":{"date-parts":[[2025,9,25]],"date-time":"2025-09-25T03:47:41Z","timestamp":1758772061000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090825819316051"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2020,1]]},"references-count":31,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2020,1]]}},"alternative-id":["S0090825819316051"],"URL":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.10.021","relation":{},"ISSN":["0090-8258"],"issn-type":[{"value":"0090-8258","type":"print"}],"subject":[],"published":{"date-parts":[[2020,1]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Genomic heterogeneity in peritoneal implants: A differential analysis of gene expression using nanostring Human Cancer Reference panel identifies a malignant signature","name":"articletitle","label":"Article Title"},{"value":"Gynecologic Oncology","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1016\/j.ygyno.2019.10.021","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2019 Elsevier Inc. All rights reserved.","name":"copyright","label":"Copyright"}]}}